Is DNA or MXCT more profitable?

MaxCyte has a net margin of -114.77% compared to Ginkgo Bioworks' net margin of -259.96%. MaxCyte's return on equity of -18.92% beat Ginkgo Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Ginkgo Bioworks -259.96% -60.27% -26.88% MaxCyte -114.77% -18.92% -16.14%

Does the media favor DNA or MXCT?

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 2 articles in the media. MaxCyte's average media sentiment score of 0.90 beat Ginkgo Bioworks' score of 0.21 indicating that MaxCyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MXCT or PACB?

In the previous week, Pacific Biosciences of California had 2 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for Pacific Biosciences of California and 2 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.90 beat Pacific Biosciences of California's score of 0.70 indicating that MaxCyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacific Biosciences of California 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MXCT or SLP more profitable?

Simulations Plus has a net margin of 9.88% compared to MaxCyte's net margin of -114.77%. Simulations Plus' return on equity of 13.50% beat MaxCyte's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -114.77% -18.92% -16.14% Simulations Plus 9.88% 13.50% 12.45%

Does the media favor MXCT or SLP?

In the previous week, Simulations Plus had 3 more articles in the media than MaxCyte. MarketBeat recorded 5 mentions for Simulations Plus and 2 mentions for MaxCyte. Simulations Plus' average media sentiment score of 1.44 beat MaxCyte's score of 0.90 indicating that Simulations Plus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MaxCyte 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Simulations Plus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, MXCT or TKNO?

Alpha Teknova has higher revenue and earnings than MaxCyte. Alpha Teknova is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MaxCyte $33.03M 3.62 -$44.63M -$0.33 N/A Alpha Teknova $40.52M 8.88 -$17.26M -$0.31 N/A

Is MXCT or TKNO more profitable?

Alpha Teknova has a net margin of -38.37% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Alpha Teknova's return on equity. Company Net Margins Return on Equity Return on Assets MaxCyte -114.77% -18.92% -16.14% Alpha Teknova -38.37% -24.94% -16.53%

MaxCyte (MXCT) Competitors

$1.16 -0.03 (-2.52%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.16 0.00 (0.00%)

As of 09/11/2026 07:36 PM Eastern

Compare

MXCT vs. DNA, PACB, SLP, TKNO, and LAB

Should you buy MaxCyte stock or one of its competitors? MaxCyte's main competitors and comparable companies include Ginkgo Bioworks (DNA), Pacific Biosciences of California (PACB), Simulations Plus (SLP), Alpha Teknova (TKNO), and Standard BioTools (LAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does MaxCyte compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability.

MaxCyte has a net margin of -114.77% compared to Ginkgo Bioworks' net margin of -259.96%. MaxCyte's return on equity of -18.92% beat Ginkgo Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-259.96%	-60.27%	-26.88%
MaxCyte	-114.77%	-18.92%	-16.14%

Ginkgo Bioworks has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by company insiders. Comparatively, 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ginkgo Bioworks presently has a consensus target price of $6.33, suggesting a potential downside of 6.15%. MaxCyte has a consensus target price of $5.00, suggesting a potential upside of 331.03%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts clearly believe MaxCyte is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MaxCyte has lower revenue, but higher earnings than Ginkgo Bioworks. MaxCyte is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	2.67	-$312.76M	-$5.01	N/A
MaxCyte	$33.03M	3.62	-$44.63M	-$0.33	N/A

In the previous week, Ginkgo Bioworks and Ginkgo Bioworks both had 2 articles in the media. MaxCyte's average media sentiment score of 0.90 beat Ginkgo Bioworks' score of 0.21 indicating that MaxCyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MaxCyte beats Ginkgo Bioworks on 10 of the 15 factors compared between the two stocks.

How does MaxCyte compare to Pacific Biosciences of California?

MaxCyte (NASDAQ:MXCT) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

68.8% of MaxCyte shares are held by institutional investors. 4.1% of MaxCyte shares are held by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Pacific Biosciences of California had 2 more articles in the media than MaxCyte. MarketBeat recorded 4 mentions for Pacific Biosciences of California and 2 mentions for MaxCyte. MaxCyte's average media sentiment score of 0.90 beat Pacific Biosciences of California's score of 0.70 indicating that MaxCyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacific Biosciences of California	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MaxCyte presently has a consensus target price of $5.00, suggesting a potential upside of 331.03%. Pacific Biosciences of California has a consensus target price of $1.71, suggesting a potential upside of 31.73%. Given MaxCyte's stronger consensus rating and higher probable upside, equities research analysts clearly believe MaxCyte is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

Pacific Biosciences of California has a net margin of -82.49% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

MaxCyte has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market.

MaxCyte has higher earnings, but lower revenue than Pacific Biosciences of California. MaxCyte is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.62	-$44.63M	-$0.33	N/A
Pacific Biosciences of California	$160.01M	2.53	-$546.38M	-$0.43	N/A

Summary

MaxCyte beats Pacific Biosciences of California on 10 of the 15 factors compared between the two stocks.

How does MaxCyte compare to Simulations Plus?

MaxCyte (NASDAQ:MXCT) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

In the previous week, Simulations Plus had 3 more articles in the media than MaxCyte. MarketBeat recorded 5 mentions for Simulations Plus and 2 mentions for MaxCyte. Simulations Plus' average media sentiment score of 1.44 beat MaxCyte's score of 0.90 indicating that Simulations Plus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MaxCyte	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Simulations Plus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 78.1% of Simulations Plus shares are held by institutional investors. 4.1% of MaxCyte shares are held by insiders. Comparatively, 19.1% of Simulations Plus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Simulations Plus has a net margin of 9.88% compared to MaxCyte's net margin of -114.77%. Simulations Plus' return on equity of 13.50% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Simulations Plus	9.88%	13.50%	12.45%

MaxCyte has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.33, meaning that its share price is 33% more volatile than the broader market.

MaxCyte currently has a consensus price target of $5.00, indicating a potential upside of 331.03%. Simulations Plus has a consensus price target of $17.25, indicating a potential downside of 6.35%. Given MaxCyte's stronger consensus rating and higher probable upside, analysts plainly believe MaxCyte is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

MaxCyte has higher earnings, but lower revenue than Simulations Plus. MaxCyte is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.62	-$44.63M	-$0.33	N/A
Simulations Plus	$79.18M	4.71	-$64.72M	$0.40	46.05

Summary

Simulations Plus beats MaxCyte on 11 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Alpha Teknova?

MaxCyte (NASDAQ:MXCT) and Alpha Teknova (NASDAQ:TKNO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Alpha Teknova has higher revenue and earnings than MaxCyte. Alpha Teknova is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.62	-$44.63M	-$0.33	N/A
Alpha Teknova	$40.52M	8.88	-$17.26M	-$0.31	N/A

In the previous week, MaxCyte had 1 more articles in the media than Alpha Teknova. MarketBeat recorded 2 mentions for MaxCyte and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.83 beat MaxCyte's score of 0.90 indicating that Alpha Teknova is being referred to more favorably in the news media.

Company	Overall Sentiment
MaxCyte	Positive
Alpha Teknova	Very Positive

MaxCyte has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Alpha Teknova has a net margin of -38.37% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Alpha Teknova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Alpha Teknova	-38.37%	-24.94%	-16.53%

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Comparatively, 13.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MaxCyte presently has a consensus price target of $5.00, indicating a potential upside of 331.03%. Alpha Teknova has a consensus price target of $7.50, indicating a potential upside of 11.77%. Given MaxCyte's higher possible upside, equities research analysts plainly believe MaxCyte is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Alpha Teknova beats MaxCyte on 9 of the 16 factors compared between the two stocks.

How does MaxCyte compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and MaxCyte (NASDAQ:MXCT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Standard BioTools has a net margin of 100.36% compared to MaxCyte's net margin of -114.77%. Standard BioTools' return on equity of -7.57% beat MaxCyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
MaxCyte	-114.77%	-18.92%	-16.14%

MaxCyte has lower revenue, but higher earnings than Standard BioTools. MaxCyte is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.17	-$74.90M	$0.22	3.14
MaxCyte	$33.03M	3.62	-$44.63M	-$0.33	N/A

Standard BioTools has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, MaxCyte has a beta of 1.52, meaning that its stock price is 52% more volatile than the broader market.

Standard BioTools currently has a consensus target price of $1.35, suggesting a potential upside of 95.65%. MaxCyte has a consensus target price of $5.00, suggesting a potential upside of 331.03%. Given MaxCyte's stronger consensus rating and higher possible upside, analysts plainly believe MaxCyte is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 26.8% of Standard BioTools shares are held by company insiders. Comparatively, 4.1% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, MaxCyte had 1 more articles in the media than Standard BioTools. MarketBeat recorded 2 mentions for MaxCyte and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.78 beat MaxCyte's score of 0.90 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Overall Sentiment
Standard BioTools	Very Positive
MaxCyte	Positive

Summary

Standard BioTools and MaxCyte tied by winning 8 of the 16 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MXCT vs. The Competition

Export

Metric	MaxCyte	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$119.72M	$9.74B	$7.16B	$12.85B
Dividend Yield	N/A	1.48%	2.57%	11.17%
P/E Ratio	-3.52	66.42	274.94	25.36
Price / Sales	3.62	108.85	685.44	117.05
Price / Cash	N/A	26.35	76.65	51.52
Price / Book	0.72	5.28	10.33	6.20
Net Income	-$44.63M	$56.67B	$3.50B	$358.50M
7 Day Performance	-9.38%	-2.15%	-3.32%	-2.35%
1 Month Performance	-16.55%	-1.93%	-0.53%	-3.23%
1 Year Performance	-20.00%	25.04%	23.51%	8.79%

MaxCyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MXCT MaxCyte	2.819 of 5 stars	$1.16 -2.5%	$5.00 +331.0%	-20.0%	$119.72M	$33.03M	N/A	80	Positive News Analyst Downgrade Gap Down
DNA Ginkgo Bioworks	1.2536 of 5 stars	$6.72 -0.9%	$6.33 -5.8%	-32.7%	$454.55M	$170.15M	N/A	640	News Coverage Analyst Forecast
PACB Pacific Biosciences of California	2.5099 of 5 stars	$1.30 +2.0%	$1.71 +32.2%	+11.1%	$402.53M	$160.01M	N/A	730	News Coverage Analyst Forecast Gap Down
SLP Simulations Plus	1.1009 of 5 stars	$18.43 +0.0%	$17.25 -6.4%	+22.4%	$372.74M	$79.18M	46.06	160	News Coverage Positive News
TKNO Alpha Teknova	2.256 of 5 stars	$6.76 -2.2%	$7.50 +11.0%	+50.8%	$362.14M	$40.52M	N/A	240	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MXCT) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MaxCyte (MXCT) Competitors

MXCT vs. DNA, PACB, SLP, TKNO, and LAB

How does MaxCyte compare to Ginkgo Bioworks?

Summary

How does MaxCyte compare to Pacific Biosciences of California?

Summary

How does MaxCyte compare to Simulations Plus?

Summary

How does MaxCyte compare to Alpha Teknova?

Summary

How does MaxCyte compare to Standard BioTools?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MaxCyte (MXCT) Competitors

MXCT vs. DNA, PACB, SLP, TKNO, and LAB

How does MaxCyte compare to Ginkgo Bioworks?

Is DNA or MXCT more profitable?

Which has more volatility and risk, DNA or MXCT?

Do institutionals & insiders believe in DNA or MXCT?

Do analysts rate DNA or MXCT?

Which has better valuation & earnings, DNA or MXCT?

Does the media favor DNA or MXCT?

Summary

How does MaxCyte compare to Pacific Biosciences of California?

Do insiders and institutionals believe in MXCT or PACB?

Does the media refer more to MXCT or PACB?

Do analysts rate MXCT or PACB?

Is MXCT or PACB more profitable?

Which has more risk and volatility, MXCT or PACB?

Which has stronger valuation and earnings, MXCT or PACB?

Summary

How does MaxCyte compare to Simulations Plus?

Does the media favor MXCT or SLP?

Do insiders and institutionals have more ownership in MXCT or SLP?

Is MXCT or SLP more profitable?

Which has more risk & volatility, MXCT or SLP?

Do analysts recommend MXCT or SLP?

Which has preferable earnings and valuation, MXCT or SLP?

Summary

How does MaxCyte compare to Alpha Teknova?

Which has higher earnings and valuation, MXCT or TKNO?

Does the media refer more to MXCT or TKNO?

Which has more volatility & risk, MXCT or TKNO?

Is MXCT or TKNO more profitable?

Do institutionals and insiders have more ownership in MXCT or TKNO?

Do analysts rate MXCT or TKNO?

Summary

How does MaxCyte compare to Standard BioTools?

Is LAB or MXCT more profitable?

Which has stronger earnings and valuation, LAB or MXCT?

Which has more volatility and risk, LAB or MXCT?

Do analysts rate LAB or MXCT?

Do institutionals & insiders believe in LAB or MXCT?

Does the media prefer LAB or MXCT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MXCT vs. The Competition

MaxCyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools